References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-176-4-3-18

nogr-1298

Research Article

ПЕРЕДОВАЯ СТАТЬЯ

LEADING ARTICLE

Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19

Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic

https://orcid.org/0000-0002-1095-8787

Гриневич

В. Б.

Grinevich

V. B.

Head of 2nd Therapy department of postgraduate education, DSci, professor

Scopus Author ID: 7005167197 St Petersburg

Кравчук

Ю. А.

Kravchuk

Yu. A.

kravchuk2003@mail.ru

https://orcid.org/0000-0002-8858-5642

Ткаченко

Е. И.

Tkachenko

E. I.

Professor of 2nd Therapy department of postgraduate education, DSci, professor

Scopus Author ID: 7102256824 St Petersburg

Першко

А. М.

Pershko

A. M.

Педь

В. И.

Ped

V. I.

Сас

Е. И.

Sas

I. E.

Губонина

И. В.

Gubonina

I. V.

Лазебник

Л. Б.

Lazebnik

L. B.

https://orcid.org/0000-0001-9331-5906

Стефанюк

О. В.

Stefanyuk

O. V.

ФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова» МО РФРоссияMilitary Medical Academy named after S. M. KirovRussian Federation

ФГБОУВО «Московский государственный медицинский стоматологический университет им. А. И. Евдокимова»РоссияFSEBI of HE “A. I. Evdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russian FederationRussian Federation

ФГБОУВО «Московский государственный медицинский стоматологический университет им. А. И. Евдокимова», ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииРоссияFSEBI of HE “A. I. Evdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russian Federation, Federal State Budgetary Institution “National Medical Research Centre for Therapy and Preventive Medicine” of the Russian Ministry of HealthRussian Federation

2020

23062020

1744318

2020

Гриневич В.Б., Кравчук Ю.А., Ткаченко Е.И., Першко А.М., Педь В.И., Сас Е.И., Губонина И.В., Лазебник Л.Б., Стефанюк О.В.

Grinevich V.B., Kravchuk Y.A., Tkachenko E.I., Pershko A.M., Ped V.I., Sas I.E., Gubonina I.V., Lazebnik L.B., Stefanyuk O.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/1298

coronavirus SARS-CoV-2энтероцитымикробиотадиареянутритивная поддержка

coronavirus SARS-CoV-2enterocytesmicrobiotadiarrheanutritional support

References1

Временные методические рекомендации МЗ РФ. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020). – 165 c.

Temporary guidelines of the Ministry of Health of the Russian Federation. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Moscow. Version 6 (04/28/2020), 165 p.

Диагностика, лечение и профилактика новой коронавирусной инфекции (COVID-19). Методические рекомендации ГВМУ МО РФ. Версия 4 от 06.04.2020 г. – 53 с.

Diagnosis, treatment and prevention of a new coronavirus infection (COVID-19). Methodical recommendations of the Main Military Medical University of the Russian Federation. Moscow, Version 4 (04/06/2020), 53 P.

Gu J., Han, B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology. 2020 Mar 3. pii: S0016–5085(20)30281-X.

Xiao F., Tang M., Zheng X., Liu Y., Li X., Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020.

Liang W., Feng Z., Rao S., Xiao O., Xue X., Lin Z. et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut 2020 Feb 26. pii: gutjnl-2020–320832. DOI: 10.1136/gutjnl-2020–320832.

Chai X., Hu L., Zhang Y. et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv 2020:2020.2002.2003.931766.

Ивашкин В.Т., Зольникова О. Ю., Охлобыстин А. В., Полуэктова Е. А., Трухманов А. С., Широкова Е. А., Шептулин А. А., Гоник М. И., Трофимовская Н. И. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020; 30(2): 7 – https://doi.org/10.22416/1382–4376–2020–30–3–7 https://doi.org/10.22416/1382-4376-2020-30-3-7

Ivashkin V. T., Sheptulin A. A., Zolnikova O. Y., et al. New coronavirus infection (COVID-19) and digestive system. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020; 30(2): 7;. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-3-7

Ungaro R.C., Sullivan T., Colombel J. F., Patel G. What Should Gastroenterologists and Patients Know About COVID-19? Clin Gastroenterol Hepatol. 2020 Mar 18. pii: S1542–3565(20)30330-X

Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? The Lancet Gastroenterology & Hepatology 2020;5: 335–337.

Han C., Duan C., Zhang S. et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol. 2020 Apr 15.

Guan W-j., Ni Z-y., Hu Y., Liang W-h., Ou C-q., He J-x. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine 2020.

Pan L., Mu M., Ren H. G., Yang P., Sun Y., Wang R. et al. Cli ni cal characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross- sectional, multicenter study. Am J Gastroenterol, 2020. DOI: 10.14309/ajg.0000000000000620.

Boettler T., Newsome P. N., Mondelli M. U., Matitic M., Cordeo E., Cornberg M. et al. Care of patients with liver disease during the COVID-19 pandemic: EASLESCMID position paper. JHEP Rep. 2020;2(3):100113-.DOI:10.1016/j.jhepr.2020.100113.

Fan Z., Chen L., Li J., Tian C., Zhang Y., Huang S. et al. Clinical Features of COVID-19-Related Liver Damage, 2020. Available at SSRN3546077. DOI: 10.2139/ssrn.3546077.

Chen N., Zhou M., Dong X., Ou J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020; 395(10223): 507–13.

Ong J., Young B. E., Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020 Mar 20. pii: gutjnl-2020–321051.

Jin X., Lian J. S., Hu J. H., Gao J., Zheng L., Zhang Y. M. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirusinfected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020. DOI:10.1136/gutjnl-2020–320926.

Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.

Hormati A., Shahhamzeh A., Afifian M., Khodadust F., Ahmadpour S. Can COVID-19 present unusual GI symptoms? J Microbiol Immunol Infect. 2020: S1684–182(20)30080–3.

Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9: F1000 Faculty Rev-69. Published 2020 Jan 31.

Гриневич В.Б., Кравчук Ю. А., Педь В. И., Арапханова М. М., Шералиев А. Р. Канцерогенез у пациентов с неалкогольной жировой болезнью печени без цирроза: роль желчных кислот и кишечной микробиоты. Экспериментальная и клиническая гастроэнтерология. 2019. № 8 (168). С. 4–10. https://doi.org/10.31146/1682-8658-ecg-168-8-4-10

Grinevich V. B., Kravchuk Y. A., Ped’ V. I., Arapkhanova M. M., Sheraliev A. R. Carcinogenesis in patients with non-alcoholic fatty liver disease without cirrhosis: the role of bile acids and intestinal microbiota. Experimental and Clinical Gastroenterology. 2019;(8):4-10. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-168-8-4-10

Гриневич В.Б., Ткачева О. Н., Егшатян Л. В., Сас Е. И., Ефимов О. И. Вклад кишечной микробиоты в патогенез инсулинорезистентности (обзор литературы). Профилактическая медицина. 2015. Т. 18. № 1. С. 54–58. https://doi.org/10.17116/profmed201518154-58

Grinevich V. N., Tkacheva O. N., Egshatyan L. V., Sas E. I., Efimov O. I. Contribution of the gut microbiota to the pathogenesis of insulin resistance (literature review). Russian Journal of Preventive Medicine and Public Health = Profi lakticheskaya meditsina. 2015;18(1):54-58. https://doi.org/10.17116/profmed201518154-58

Гриневич В.Б., Кравчук Ю. А., Сас Е. И., Ре шет нева Е. М. Пребиотическая терапия в комплексном лечении больных смешанными стеатогепатитами. Вестник Северо-Западного государственного медицинского университета им. И. И. Мечникова. 2015. Т. 7. № 1. С. 68–73.

Grinevich V. B., Kravchuk Y. A., Sas E. I., Reshetneva E. M. Prebiotic therapy in complex treatment of patients with steatohepatitis mixed. Herald of the northwestern state medical University named after I.I. Mechnikov. 2015, vol. 7, No 1, pp. 68–73.

Руководство по профилактике и лечению новой коронавирусной инфекции COVID-19. Первая академическая клиника Университетской школы медицины провинции Чжэцзян. Составлено на основе клинической практики. Под ред. Тинбо Лян. – 89 с.

Guidelines for the prevention and treatment of new coronavirus infection COVID-19. The first academic clinic of Zhejiang University School of Medicine. Compiled on the basis of clinical practice. Ed. Tingbo Liang. 89 P.

Шендеров Б.А., Ткаченко Е. И., Лазебник Л. Б., Ардатcкая М. Д., Синица А. В., Захарченко М. М. Метабиотики – новая технология профилактики и лечения заболеваний, связанных с микроэкологическими нарушениями в организме человека. Экспериментальная и клиническая гастроэнтерология. 2018. № 3 (151). С. 83–92.

Shenderov B. A., Tkachenko E. I., Lazebnik L. B., Ardatskaya M. D., Sinitsa A. V., Zakharchenko M. M. Metabiotics – novel technology of protective and treatment of diseases associated with microecological imbalance in human being. Experimental and Clinical Gastroenterology. 2018;(3):83-92. (In Russ.)

Hahm K.B., Kim D. H., Lee K. M. et al. Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther. 2003;18 Suppl 1:24–38.

Lai Y., Zhong W., Yu T. et al. Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin. PLoS One. 2015 Jul 2;10(7): e0132031.

Otani K., Tanigawa T., Watanabe T. et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22–28.

Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261–270.

Arakawa T, Higuchi K, Fujiwara Y et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig. Dis. Sci. 50(Suppl. 1) S3–S11 (2005)

Robert M. G. Review article: The role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Alimentary Pharmacology & Therapeutics. 2003. 18 Suppl 1(s1):8–13

Matysiak-Budnik T., Heyman M., Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther 2003; 18 (Suppl. 1): 55–62.;

Jaafar M.H., Safi S. Z., Tan M. P., Rampal S., Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018; 63(5):1250–1260.

Hayashi S., Sugiyama T., Amano К. et al. Effect of Rebamipide, a Novel Antiulcer Agent, on Helicobacter pylori Adhesion to Gastric Epithelial Cells. Antimicrobial Agents And Chemotherapy. 1998, Vol. 42, No. 8. P. 1895–1899

Симаненков В.И., Бакулина Н. В., Филь Т. С., Хубиева А. Х. Оценка эффективности эрадикации Н. Pylori при добавлении к схеме лечения цитопротективного препарата ребамипид: результаты исследования Бастион. Фарматека – 2017. S5. с. 65–70

V. I. Simanenkov, N. V. Bakulina, Т. S. Fil, A. Kh. Khubieva Evaluation of efficiency of h. Pylori eradication in case of addition of cytoprotective preparation rebamipide to the treatment: results of the bastion trial. Farmateka. 2017;s5:65-70.

Andreev D.N., Maev I. V., Dicheva D. T. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies J. Clin. Med. 2019, 8 (9), 1498

Pittayanon R., Piyachaturawat P., Rerknimitr R et al. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double‐blind placebo‐controlled trial J. Gastroenterology and Hepatology. 2019. Vol.34, Iss.9. P. 1517–1522

Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis, Dig Dis Sci. 2013 Jul;58(7):1991–2000

Watanabe T., Takeuchi T., Handa O. et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage. PLoS One. 2015; 10(4): e0122330

Yamashita Т., Watanabe Е., Ikeda Т. et al. Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with non-valvular atrial fi brillation. Journal of Arrhythmia. 2014. Vol. 30, Iss. 6, P. 478–484

Ивашкин В.Т., Маев И. В., Царьков П. В. и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Рос журн гастроэнтерол гепатол колопроктол. 2020;30(1):49–70. https://doi.org/10.22416/1382-4376-2020-30-1-49-70

Ivashkin V. T., Maev I. V., Tsar’kov P. V., et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49-70. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-1-49-70

Ивашкин В.Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол 2018;28(1):55–70 https://doi.org/10.22416/1382-4376-2018-28-1-55-70

Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-1-55-70

Лазебник Л.Б., Ткаченко Е. И., Абдулганиева Д.И и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter Pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017;(2):3–21.

Lazebnik L. B., Tkachenko E. I., Abdulganiyeva D. I., et al. VI National guidelines for the diagnosis and treatment of acid-related and helicobacter pylori-associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;(2):3-21. (In Russ.)

Каратеев А.Е., Насонов Е. Л., Ивашкин В. Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1–29. https://doi.org/10.14412/1995-4484-2018-1-29

Karateev A. E., Nasonov E. L., Ivashkin V. T., Martynov A. I., Yakhno N. N., Arutyunov G. P., Alekseeva L. I., Abuzarova G. R., Evseev M. A., Kukushkin M. L., Kopenkin S. S., Lila A. M., Lapina T. L., Novikova D. S., Popkova T. V., Rebrov A. P., Skorobogatykh K. V., Chichasova N. V. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1-29. (In Russ.) https://doi.org/10.14412/1995-4484-2018-1-29

Лазебник Л.Б., Голованова Е. В., Алексеенко С. А. и др. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология. 2018;151(03):04–18

Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Recommendations for the prevention and treatment of esophago-gastro-entero-colopathy induced by nonsteroidal antiinflammatory drugs “NSAID”. Experimental and Clinical Gastroenterology. 2018;(3):4-18. (In Russ.)

Оганов Р. Г., Симаненков В. И., Бакулин И. Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019. Т. 18. № 1. С. 5–66. https://doi.org/10.15829/1728-8800-2019-1-5-66

Oganov R. G., Simanenkov V. I., Bakulin I. G., et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.) https://doi.org/10.15829/1728-8800-2019-1-5-66

Satoh K., Yoshino J., Akamatsu T. et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol. 2016 Mar;51(3):177–94.

Oh J.H., Kwon J. G., Jung H.K et al. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil. 2020 Jan 30;26(1):29–50.

Pimentel-Nunes P., Libânio D., Marcos-Pinto R. et al. Ma nage ment of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019 Apr;51(4):365–388.

Fujishiro M., Iguchi M., Kakushima N. et al. Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding. Dig Endosc. 2016 May;28(4):363–378.

Ono H., Yao K., Fujishiro M. et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc. 2016 Jan;28(1):3–15.

Pittayanon R., Leelakusolvong S., Vilaichone R. K. et al . Tha i la nd Dyspepsia Guidelines: 2018. J Neurogastroenterol Motil. 2019;25(1):15‐26.

Nakamura K., Iwata Yi., Asai J. et al. Guidelines for the treatment of skin and mucosal lesions in Behçet’s disease: A secondary publication. The Journal of Dermatology Volume47, Issue3 March 2020 Pages223–235).

Yasuda T., Chiba H., Satomi T. et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res. 2012;2(4): e3. Published 2012 Jan 1.

Takeji Y, Urashima H., Aoki A., Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012 Jun;28(3):259–63.

Matsuda T., Ohno S., Hirohata S. et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study. Drugs R D.2003;4 (1): 19–28.

Akagi S., Fujiwara T., Nishida M. et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019; 5: 16.

Гриневич В. Б. Пребиотическая коррекция микробно-тканевого комплекса кишечника, как базовая составляющая современной патогенетической терапии метаболического синдрома и ассоциированных кардиоваскулярных и цереброваскулярных заболеваний. Учебно-методическое пособие / В. Б. Гриневич, Е. И. Сас, В. Е. Кон [и др.]. – СПб., 2012. – 20 с.

Grinevich V. B., Sas E. I., Cohn V. E., et al. Prebiotic correction of the microbial-tissue complex of the intestine, as a basic component of modern pathogenetic therapy of the metabolic syndrome and associated cardiovascular and cerebrovascular diseases. SPb., 2012, 20 P.

Чучалин А. Г., Синопальников А. И., Козлов Р. С. и соавт. Клинические рекомендации по диагностике и лечению тяжелой внебольничной пневмонии у взрослых. – М., 2014. –82 с.

Chuchalin A. G., Sinopalnikov A. I., Kozlov R. S. et al. Clinical recommendations for the diagnosis and treatment of severe community-acquired pneumonia in adults. Moscow, 2014, 82 P.

Першко А.М., Гриневич В. Б., Иванюк Е. С. Нутриционная поддержка в многопрофильном стационаре: учебно-методическое пособие. – СПб, ВМедА, 2020. –31 с.

Pershko A. M., Grinevich V. B., Ivanyuk E. S. Nutritional support in a multidisciplinary hospital: a teaching tool. SPb, VmedA. Publ., 2020, 31 P.

Bear D.E., Wandrag L., Merriweather J. L. et al. Enhanced Recovery After Critical Illness Programme Group (ERACIP) investigators. The role of nutritional support in the physical and functional recovery of critically ill patients: a narrative review. Crit Care. 2017 Aug 26;21(1):226. doi: 10.1186/s13054–017–1810–2.

van Zanten A. R.H., De Waele E., Wischmeyer P. E. Nutrition Therapy and Critical Illness. Practical Guidance for the ICU, Post-ICU, and Long-Term Convalescence Phases. Crit. Care. – 2019, – Vol. 23, № 368.

van Zanten A. R.H., De Waele E., Wischmeyer P. E. Nutrition Therapy and Critical Illness. Practical Guidance for the ICU, Post-ICU, and Long-Term Convalescence Phases. \Crit. Care. – 2019, – Vol. 23, № 368.

Casaer M.R., Mesotten D., Hermans G. et al. Early versus late parenteral nutrition in critically ill patients. N Engl J Med 2011; 365: 506–17

Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020.

Mao R., Liang J., Shen J. et al. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020; 5(5):426–428.

Walls A.C., Park Y-J., Tortorici M. A., Wall A., McGuire A. T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020.

Boggs W. Liver Injury Common With COVID-19. March 13, 2020 https://www.medscape.com/viewarticle/926628

Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. doi: 10.1111/LIV.14470

Albillos A., Lario M., Álvarez-Mon M. Cirrhosisassociated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology 2014;61:1385–1396.

Xu Z., Shi L., Wang Y. et al. Pathological fi ndings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020.

Li X., Geng M., Peng Y., Meng L., Lu S. Molecular immune pathogenesis and diagnosis of COVID19. Journal of Pharmaceutical Analysis 2020.

Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R. S., Manson J. J. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 2020.

Zhang C., Shi L., Wang F-S. Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology 2020. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper 17

Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver International 2020; n/a.

Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests [published online ahead of print, 2020 Apr 13]. J Hepatol. 2020; S0168–8278(20)30218-X. doi:10.1016/j.jhep.2020.04.006

Schütte A., Ciesek S., Wedemeyer H., Lange C. M. Influenza virus infection as precipitating event of acute-on-chronic liver failure. Journal of Hepatology 2019;70:797–799.

Mroz M.S.1, Harvey B. J. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells. Steroids. 2019 Nov; 151: 108461.

Schultz F., Hasan A., Alvarez-Laviada A. The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts. Prog Biophys Mol Biol. 2016 Jan;120(1–3):149–63.

Işık S., Karaman M., Çilaker M. S. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017 45(4):339–349.

Niu F., Xu X., Zhang R. et al. Ursodeoxycholic acid stimulates alveolar fluid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J Cell Physiol. 2019 Nov;234(11):20057–20065.

Hollander J.E., Carr B. G. Virtually Perfect? Telemedicine for Covid-19. New England Journal of Medicine 2020.

Maurice J.B., Brodkin E., Arnold F. et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. Journal of Hepatology 2016;65:899–905.

Zhu L., Xu X., Ma K., Yang J., Guan H., Chen S. et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. American Journal of Transplantation 2020; n/a.

Colaneri M., Seminari E., Piralla A., Zuccaro V., Filippo A. D., Baldanti F. et al. Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. Journal of Hospital Infection.

Chandok N., Watt K. D. S. Pain Management in the Cirrhotic Patient: The Clinical Challenge. Mayo Clinic Proceedings 2010;85:451–458.

IOIBD Update on COVID19 for Patients with Crohn’s Disease and Ulcerative Colitis | IOIBD. https://www.ioibd.org/ioibd-update-on-covid19-for-patients-withcrohns-disease-andulcerative-colitis/. Accessed April 1, 2020

Wu Y., Guo C., Tang L. et al. Prolonged presence of SARSCoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020;0(0). doi:10.1016/S2468–1253(20)30083–2

Current Data | Secure-IBD Database. https://covidibd.org/current-data/. Accessed April 18, 2020

Taxonera, C., Sagastagoitia, I., Alba, C., Mañas, N., Olivares, D. and Rey, E. (2020), 2019 Novel Coronavirus Disease (COVID‐19) in patients with Infl ammatory Bowel Diseases. Aliment Pharmacol Ther. Accepted Author Manuscript. doi:10.1111/apt.15804.

BSG expanded consensus advice for the management of IBD during the COVID-19 pandemic. The British Society of Gastroenterology. Published March 30, 2020. Accessed March 31, 2020

Cheng K-W., Cheng S-C., Chen W-Y. et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015;115:9–16. doi:10.1016/j.antiviral.2014.12.011

De Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011; 92(Pt 11):2542–2548. doi:10.1099/vir.0.034983–0

Monteleone G., Ardizzone S. Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection? Journal of Crohn’s and Colitis, 2020, 1–3 doi:10.1093/ecco-jcc/jjaa061

Gastroenterology professional society guidance on endoscopic procedures during the COVID-19 pandemic | American Gastroenterological Association. https://www.gastro.org/practice-guidance/practice-updates/covid-19/gastroenterologyprofessional-society-guidance-on-endoscopic-procedures-during-the-covid-19-pandemic. Accessed April 3, 2020.

Carbajo-Lozoya J., Muller M. A., Kallies S., Thiel V., Drosten C., von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165(1):112–117. doi:10.1016/j.virusres.2012.02.002

Harmer D., Gilbert M., Borman R., Clark K. L. Quantitative mRNA expression profi ling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002;532:107–10.

Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020. doi: 10.1001/jama.2020.3786.

Ивашкин В. Т. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2017;27(5):76-93 https://doi.org/10.22416/1382-4376-2017-27-5-76-93

Ivashkin V. T., Shelygin Y. A., Baranskaya Y. K., et al. Dia gno sis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-5-76-93

Клинические Рекомендации Российского Общества Хирургов, Ассоциации гепатопанкреатобилиарных хирургов стран СНГ «Острый панкреатит» – М., 2015. – 38 с.

Clinical Recommendations of the Russian Society of Surgeons, the Association of hepatopancreatobiliary surgeons of the CIS countries “Acute pancreatitis”. Moscow, 2015, 38 p.

100

Клинические Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению хронического панкреатита / Под ред. Ивашкина В. Т., Маева И. В., Шифрина О. С. и др. – М., 2014. – 45 с.

Ivashkin V. T., Maev I. V., Shifrin O. S. et al. Clinical Recommendations of the Russian Gastroenterological Association for the Diagnosis and Treatment of Chronic Pancreatitis. Moscow, 2014, 45 p.

101

Ивашкин В.Т., Маев И. В., Охлобыстин А. В., Алексеенко С. А., Белобородова Е. В., Кучерявый Ю. А., Лапина Т. Л., Трухманов А. С., Хлынов И. Б., Чикунова М. В., Шептулин А. А., Шифрин О. С. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению экзокринной недостаточности поджелудочной железы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(2):72–100. https://doi.org/10.22416/1382-4376-2018-28-2-72-100

Ivashkin V. T., Mayev I. V., Okhlobystin A. V., et al. Diagnos tics and treatment of pancreatic exocrine insufficiency: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(2):72-100. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-2-72-100

102

Временные рекомендации по ведению больных COVID19 и эндокринными заболеваниями / Под ред. Гринева Е. Н., Халимова Ю. Ш., Бабенко А. Ю. и др. – Медицинской Ассоциацией Эндокринологов Санкт-Петербурга, 2020 г. – 9 с.

Grinev E. N., Halimov Yu. S., Babenko A. Yu. et al. Temporary recommendations for the management of patients with COVID19 and endocrine diseases. Medical Association of Endocrinologists of St. Pe tersburg, 2020, 9 p.

The authors declare that there are no conflicts of interest present.